10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2016 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2016 10-K (Filed: Feb 23, 2017) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | |
| Revenues | $ 52,824 | 48,851 | 49,605 |
| Costs and expenses: | |||
| Cost of sales | 12,329 | 9,648 | 9,577 |
| Selling, informational and administrative expenses | 14,837 | 14,809 | 14,097 [1] |
| Research and development expenses | 7,872 | 7,690 | 8,393 |
| Amortization of intangible assets | 4,056 [2] | 3,728 | 4,039 |
| Restructuring charges and certain acquisition-related costs | 1,724 | 1,152 | 250 |
| Other (income)/deductionsnet | 3,655 | 2,860 | 1,009 |
| Income from continuing operations before provision for taxes on income | 8,351 | 8,965 | 12,240 |
| Provision for taxes on income | 1,123 | 1,990 | 3,120 |
| Income from continuing operations | 7,229 | 6,975 | 9,119 |
| Discontinued operations: | |||
| Income from discontinued operationsnet of tax | 16 | 17 | (6) |
| Gain/(loss) on disposal of discontinued operationsnet of tax | 0 | (6) | 55 |
| Discontinued operationsnet of tax | 17 | 11 | 48 |
| Net income before allocation to noncontrolling interests | 7,246 | 6,986 | 9,168 |
| Less: Net income attributable to noncontrolling interests | 31 | 26 | 32 |
| Net income attributable to Pfizer Inc. | 7,215 | 6,960 | 9,135 |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.18 | 1.13 | 1.43 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.00 | 0.01 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.18 | 1.13 | 1.44 |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.17 | 1.11 | 1.41 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.00 | 0.01 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.17 | 1.11 | 1.42 |
| Weighted-average sharesbasic | 6,089 | 6,176 | 6,346 |
| Weighted-average sharesdiluted | 6,159 [3] | 6,257 | 6,424 |
| Cash dividends paid per common share (in dollars per share) | 1.20 | 1.12 | 1.04 |
| [1] Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets. | |||
| [2] Amounts may not add due to rounding. | |||
| [3] Amount for 2016 reflects the adoption of a new accounting standard, as of January 1, 2016, that requires when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B). | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2016 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |